Shanghai and Beijing-based biopharma firm Everest Medicines, which addresses critical unmet medical needs for patients in Greater China and other parts of Asia, has appointed pharmaceutical industry veteran Wende Chen as its chief commercial officer. 11 May 2019
Notching up another defection from Novartis’ generics/biosimilars subsidiary, Icelandic biopharmaceutical company Alvotech today announced the appointment of Mark Levick as chief executive, effective August 5, 2019. 9 May 2019
In its pursuit to address the entire scope of Alzheimer's disease (AD), Japanese pharma major Eisai’s US subsidiary is expanding its AD business with the immediate appointments of two renowned experts in the neuroscience field. 4 May 2019
US biotech firm bluebird bio has appointed Joanne Smith-Farrell to chief business officer. In this role, she will lead corporate development and strategy, and she will also continue to serve as our oncology franchise leader. 2 May 2019
Swedish Orphan Biovitrum, the Nordic biotech company known as Sobi, has appointed Amy Pott as the new head of Sobi North America. She takes over effective today, replacing Rami Levin who is leaving Sobi. 30 April 2019
Brent Saunders, the chief executive and chairman of Ireland-headquartered drugmaker Allergan, will suddenly be feeling a lot better ahead of the company’s annual meeting of shareholders on May 1. 17 April 2019
Financing and creating enduring confidence around a deal like Takeda’s $62 million purchase of Shire is not straight forward, but the Japanese drugmaker has hired one of the best operators in his field to help with the task. 16 April 2019
British biotech Kymab has appointed Simon Sturge as its new chief executive, effective 1 May 2019. Mr Sturge will replace David Chiswell, who has been in the role since 2015. 10 April 2019
The nominations committee of Swedish firm Calliditas Therapeutics has proposed that Elmar Schnee becomes a board member and chairman of the company. 5 April 2019
Japanese drug major Astellas Pharma (TYO: $4503) has announced two recent senior-level promotions and one new hire within its Medical and Development (M&D) organization. 4 April 2019
French privately-held biotech firm Enterome Bioscience has named Jan Fagerberg its new chief medical officer and Catherine Mathis its chief development officer. 3 April 2019
Daniel Welch, the man who previously headed up several biotechs that were sold to pharma majors over the past several years, has joined privately-held US biopharma company InCarda Therapeutics as executive chairman. 3 April 2019
Botox (onabotulinumtoxinA) manufacturer Allergan has accepted calls to shake up its management structure, agreeing to create a new position to stand alongside the chief executive at the time of the next leadership change. 25 March 2019
California, USA-based biopharma company Tenaya Therapeutics, which is focused on developing potentially curative treatments for heart disease, today announced that it has strengthened its leadership team. 14 March 2019
Richard Francis will be stepping down as chief executive of Sandoz, the Novartis generics and biosimilars division, and as a member of the executive committee of Novartis on March 31, 2019. 14 March 2019
Keld Flintholm Jørgensen has been appointed chief business officer (CBO) heading corporate strategy and business development at Danish CNS specialist Lundbeck. 8 March 2019
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024